Healthcare Industry News: AcelRx Pharmaceuticals
News Release - January 14, 2019
SutroVax Announces Executive AppointmentsJane Wright-Mitchell appointed General Counsel
Elaine Sun promoted to Chief Strategy Officer
FOSTER CITY, Calif., Jan. 14, 2019 -- (Healthcare Sales & Marketing Network) -- SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the appointment of Jane Wright-Mitchell as General Counsel and promotion of Elaine Sun to Chief Strategy Officer and Chief Financial Officer.
Ms. Sun has served as Chief Financial Officer for SutroVax since January 2017. Her expanded role will include responsibility for SutroVax's financial, corporate development and strategy functions. Ms. Sun is a veteran strategic financial and business advisor. Her previous experience includes serving as managing director and head of West Coast health care for Evercore Partners and a managing director at Merrill Lynch and Co. in the Healthcare Investment Banking Group. Ms. Sun received a B.A. in Economics and Japanese Studies from Wellesley College and an M.B.A. from Harvard Business School.
"Jane's extensive experience guiding legal and compliance areas in both development and commercial stage companies will be vital to support our growth plans at SutroVax," said Grant Pickering, CEO and Founder. "Elaine has been instrumental in the Company's significant strategic and financial accomplishments over the last two years. Her leadership and expanded responsibilities will be central to achieving our objectives."
SutroVax is an independent vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax conjugate vaccines are developed utilizing the Company's exclusive rights to Sutro Biopharma's Xpress CF™ Platform, a cell-free protein synthesis technology. The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates. SutroVax is utilizing these more potent conjugates to develop, among other programs, a broader-spectrum pneumococcal conjugate vaccine. For more information, visit www.sutrovax.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.